Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignancies

12 Sept 2024

Abstract excerpt

Chimeric antigen receptor (CAR) T-cell therapy has achieved significant success in achieving durable and potentially curative responses in patients with hematological malignancies. CARs are tailored fusion proteins that direct T cells to a specific antigen on tumor cells thereby eliciting a targeted immune response. The approval of several CD19-targeted CAR T-cell therapies has resulted in a notable surge in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Viral Infectious Diseases and Gene Expression in Insects
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39289094
DOI: 10.1016/j.blre.2024.101241

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignanciesPMID 39289094Read ↗

Chimeric Antigen Receptor (CAR) T Cells: A Detailed Review of Origins, Engineering, and Therapeutic ImpactSemantic proximity Read ↗

Future perspectives on novel CAR-T therapeutics beyond CD19 and BCMA in onco-hematologySemantic proximity Read ↗

Chimeric antigen receptor-modified T cells strike backSemantic proximity Read ↗

Immunogenicity of CAR T cells in cancer therapy.Semantic proximity Read ↗

CAR‐T‐cell products in solid tumors: Progress, challenges, and strategiesSemantic proximity Read ↗

CAR therapy: the CD19 paradigmSemantic proximity Read ↗

Chimeric Antigen Receptor T-Cell Therapy: What We Expect SoonSemantic proximity Read ↗

CAR-T Cell TherapySemantic proximity Read ↗

CAR-T-Cell Therapy: Present Progress and Future strategiesSemantic proximity Read ↗

The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomasSemantic proximity Read ↗

Chimeric Antigen Receptors: A Paradigm Shift in ImmunotherapySemantic proximity Read ↗

Design and implementation of adoptive therapy with chimeric antigen receptor‐modified T cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.